Therapeutic node dissections in malignant melanoma

Annals of Surgical Oncology

Volumn 5, Issue 6, 1998, Pages 473-482

  Karakousis, Constantine P ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b Millard Fillmore Gates Circle Hospital   (United States)

Author keywords

Lymphadenectomy; Malignant melanoma; Nodal basin; Therapeutic node dissection regional nodal recurrence

Indexed keywords

ADJUVANT CHEMOTHERAPY; ALGORITHM; AXILLARY LYMPH NODE; CANCER INVASION; CANCER RECURRENCE; CANCER SURGERY; CERVICAL LYMPH NODE; INGUINAL LYMPH NODE; LYMPH NODE DISSECTION; MELANOMA; REVIEW;

ALGORITHMS; ARM; AXILLA; GROIN; HUMANS; LEG; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MELANOMA; NECK; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0031666172     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02303638     Document Type: Review

References (63)

1. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977;297:627-30.
2. Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Cancer 1978;41:948-56.
3. Balch CM, Soong S-J, Bartolucci AA, Urist MM, Karakousis CP, et al. Efficacy of an elective regional lymph node dissection of 1-to 4-mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-66.
4. Morton DL, Wen D-R, Wong JH, et al. Technical details of intraoperative mapping for early stage melanoma. Arch Surg 1992;127: 392-9.
5. Karakousis CP, Balch CM, Urist MM, Ross MI, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the multi-institutional randomized surgical trial. Ann Surg Oncol 1996;3:446-52.
6. Konstadoulakis M, Karakousis CP, Walsh D, Ricaniadis N. Survival of patients with stage IA malignant melanoma. Surg Oncol 1995;4:101-4.
7. Wong JH, Cagle LA, Morton DL. Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site. Arch Surg 1987;122:1380-3.
8. Karakousis CP, Emrich LJ, Driscoll DL, Rao U. Survival after groin dissection for malignant melanoma. Surgery 1991;109:119-26.
9. Shaw JHF, Koea J. Morbidity of lymphadenectomy for melanoma. Surg Oncol Clin North Am 1992;1:195-203.
10. Kane M, McClay E, Bellet RE. Frequency of occult residual melanoma after excision of a clinically positive regional lymph node. Ann Surg 1987;205:88-9.
11. Karakousis CP, Rizos S, Driscoll DL. Residual nodal disease after excisional biopsy of a palpable, positive node in melanoma. Am J Surg 1994;168:69-70.
12. Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 1997;4:252-8.
13. Buzaid AC, Tinoco L, Ross MI, Legha SS, Benjamin RS. Role of computed tomography in the staging of patients with loco-regional metastases of melanoma. J Clin Oncol 1995;13:2104-8.
14. Karakousis CP, Velez A, Driscoll DL, Takita H. Metastasectomy in malignant melanoma. Surgery 1994;115:295-302.
15. O'Brien CJ, Fisher SR. Neck dissection and parotidectomy. In: Balch CM, Houghton AN, Sober AJ, Soong S-j, eds. Cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical Publishing, 1998: 245-57.
16. O'Brien CJ, Peterson-Schaefer K, Ruark D, Coates AS, Menzie SJ, Harrison RI. Radical, modified and selective neck dissection for cutaneous malignant melanoma. Head Neck 1995;17:232-41.
17. Mansfield PF, Ames FC, Balch CM. Axillary lymph node dissection. In: Balch CM, Houghton AN, Sober AJ, Soong S-j, eds. Cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical Publishing, 1998:259-68.
18. Balch CM. Axillary lymph node dissection: differences in goals and techniques when treating melanoma and breast cancer. Surgery 1990;108:118-9.
19. Coit DG. Extent of groin dissection for melanoma. Surg Oncol Clin North Am 1992;1:271-80.
20. Karakousis CP. The technique of popliteal lymph node dissection. Surg Gynecol Obstet 1980;151:420-3.
21. Coit DG, Peters M, Brennan MF. A prospective randomized trial of perioperative Cefazolin treatment in axillary and groin dissection. Arch Surg 1991;126:1366-72.
22. Urist MM, Maddox WA, Kennedy JE, Balch CM. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. Cancer 1983;51:2152-6.
23. Stringer SP, Cassisi NJ. Radical and modified neck dissection. In: Bland K, Karakousis CP, Copeland E, eds. Atlas of Surgical Oncology. Philadelphia: WB Saunders. 1995:165-80.
24. Karakousis CP, Goumas W, Rao U, Driscoll DL. Axillary node dissection in malignant melanoma. Am J Surg 1991;162:202-7.
25. Karakousis CP, Hena MA, Emrich LJ, Driscoll DL. Axillary node dissection in malignant melanoma: Results and complications. Surg 1990;108:10-7.
26. Karakousis CP, Driscoll DL, Rose B, Walsh DL. Groin dissection in malignant melanoma. Ann Surg Oncol 1994;1:271-7.
27. Beitsch P, Balch C. Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node dissection. Am J Surg 1992;164:462-5.
28. Rapaport DP, Stadelman WK, Reintgen DS. Inguinal lymphadenectomy. In: Balch CM, Houghton AN, Sober AJ, Soong S-j, eds. Cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical Publishing, 1998:269-80.
29. Stadelmann WK, Rapaport DP, Soong S-j, Reintgen DS, Buzaid AC, Balch CM. Prognostic clinical and pathologic features. In: Balch CM, Houghton AN, Sober AJ, Soong S-j, eds. Cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical Publishing, 1998: 11-35.
30. Tillman DM, Aitchison T, Watt DC, Mackie RM. Stage II melanoma in the West of Scotland, 1976-1985: prognostic factors for survival. Eur J Cancer 1991;27:870-6.
31. Buzaid AC, Ross MI, Soong S-j. Classification and staging. In: Balch CM, Houghton AN, Sober AJ, Soong S-j, eds. Cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical Publishing, 1998: 37-47.
32. Buzaid AC, Tinoco LA, Jendiroba D, et al. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol 1995;13:2361-8.
33. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991;214: 491-9.
34. Bevilacqua RG, Coit DG, Rogatko A, Younes RN, Brennan MF. Axillary dissection in melanoma. Prognostic variables in node-positive patients. Ann Surg 1990;212:125-31.
35. Barth RJ Jr, Venzon DJ, Baker AR. The prognosis of melanoma patients with metastases to two or more lymph node areas. Ann Surg 1991;214:125-30.
36. Dale PS, Foshag LJ, Wanek LA, Morton DL. Metastasis of primary melanoma to two separate lymph node basins: prognostic significance. Ann Surg Oncol 1997;4:13-8.
37. O'Brien CJ, Peterson-Schaefer K, Stevens GN, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck 1997;19:589-94.
38. Coit DG. Prognostic factors in patients with melanoma metastatic to regional nodes. Surg Oncol Clin North Am 1992;1:281-95.
39. Warso MA, Das Gupta TK. Melanoma recurrence in a previously dissected nodal basin. Arch Surg 1994;129:252-5.
40. Kretschmer L, Lautenschlager C, Preusser KP, Fiedler H, Hetschkol. Axillary recurrence after lymph node excision in malignant melanoma. Langenbecks Arch fur Chirurgie 1993;378:4-11.
41. Kretschmer L, Lautenschlager C, Preusser KP, Ffiedler H. Inguinal recurrence after therapeutic lymphadenectomy in malignant melanoma. Langenbecks Arch fur Chirurgie 1993;378:211-6.
42. Byers RM. The role of modified neck dissection in the treatment of cutaneous melanoma of the head and neck. Arch Surg 1986;12: 1338-41.
43. Munsour PD, Sause WT, Avent JM, Noyes RD. Local control following therapeutic nodal dissection for melanoma. J Surg Oncol 1993;54:18-22.
44. Karakousis CP, Driscoll DL. Positive deep nodes in the groin and survival in malignant melanoma. Am J Surg 1996;171:421-2.
45. McCarthy JH, Haagensen CK-D, Herter FP. The role of groin dissection in the management of melanoma of the lower extremity. Ann Surg 1974;179:156-9.
46. Cohen MH, Schour L, Felix EL, et al. Staging laparotomy in the treatment of metastatic melanoma of the lower extremities. Ann Surg 1976;182:710-4.
47. Singletary SE, Schallenberger R, Guinee VF. Surgical management of groin nodal metastases from primary melanoma of the lower extremity. Surg Gynecol Obstet 1992;174:195-200.
48. Coit DG, Brennan MF. Extent of lymph node dissection in melanoma of the trunk or lower extremity. Arch Surg 1989;124:162-6.
49. Fortner JG, Booher RJ, Pack GT. Results of groin dissection for malignant melanoma in 220 patients. Surgery 1964;55:485-94.
50. Finck SJ, Giuliano AE, Mann D, Morton DL. Results of ilioinguinal dissection for stage II melanoma. Ann Surg 1982;196:180-6.
51. Jonk A, Kroon BB, Rumke P, van der Esch EP, Hart AA. Results of radical dissection of the groin in patients with stage II melanoma and histologically proved metastases of the iliac or obturator nodes, or both. Surg Gynecol Obstet 1988;167:28-32.
52. Kissin MW, Simpson DA, Easton D, White H, Westbury G. Prognostic factors related to survival and groin recurrence following therapeutic lymph node dissection for lower limb malignant melanoma. Br J Surg 1987;74:1023-6.
53. McNeer G, Das Gupta TK. Prognosis in malignant melanoma. Surgery 1964;56:512-8.
54. Cohen MH, Ketcham AS, Felix EL, et al. Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma. Ann Surg 1977;186:635-42.
55. Das Gupta TK. Results of treatment of 269 patients with primary cutaneous melanoma: a five-year prospective study. Ann Surg 1977;186:201-9.
56. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma, III: prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981;193:377-88.
57. Callery C, Cochran AJ, Roc DJ, et al. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. Ann Surg 1982;196:69-75.
58. Roses DF, Provet JA, Harris MN, Gumport SL, Dubin N. Prognosis of patients with pathologic stage II cutaneous malignant melanoma. Ann Surg 1985;201:103-7.
59. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
60. Burmeister BH, Smithers BM, Poulsen M, McLeod GR, Bryant G, Tripcong L, Thorpe C. Radiation therapy for nodal disease in malignant melanoma. World J Surg 1995;19:369-71.
61. Strom EA, Ross MI. Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control. Ann Surg Oncol 1995;2:445-9.
62. Petrek JA, Blackwood MM. Axillary dissection: current practice and technique. Curr Probl Surg 1995;32:257-323.
63. Morton DL, Hoon DSB, Nizza JA, et al. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann N Y Acad Sci 1993;690:120-34.